Pharmaceutical Breakthroughs is dedicated to fostering a deep understanding of novel developments, advancements, and breakthroughs in the field of pharmaceutical sciences. Our journal aims to be a platform for researchers, scientists, clinicians, and industry professionals to share their insights, discoveries, and perspectives in the realm of pharmaceutical innovation.
Dr. T. M. Aminabhavi, a distinguished academic, served as the Founder Director of the Center of Excellence in Polymer Science at Karnatak University, Dharwad. With roles ranging from Professor of Physical Chemistry to academic leadership, he has significantly contributed to polymer science, physical chemistry, and environmental engineering. His recent assignments include membership in the CEFIPRA - IRC Committee and the CSIR Research Funding Committee. Internationally engaged, he holds a Visiting Adjunct Professorship at Korea University and has collaborated with institutions across France, China, the USA, and more. In addition to academia, Dr. Aminabhavi has consulted for renowned organizations like Paul Hastings and Reliance Life Sciences. His extensive research spans materials for energy, membranes, pharmacy, and theoretical studies, reflecting in numerous patents and scholarly publications. As Founder President of the Society for Polymer Science, India, and Chairman of the Scientific Advisory Board at SDPC, Surat, Dr. Aminabhavi has demonstrated leadership in advancing knowledge and addressing environmental challenges.
Dr. Stuart Maudsley currently holds the Odysseus Chair in Receptor Pharmacology and is also the Group Leader of the Receptor Biology Laboratory at the University of Antwerp. In addition to this, he is the Co-Founder of the therapeutic discovery start-up HeptOME. He has served as the Adjunct Director of the VIB Department of Molecular Genetics as well as Chair of the Department of Biomedical Science at the University of Antwerp. His research focuses on the age-dependent changes in receptor pharmacology associated with complex diseases driven by molecular gerontological signaling, e.g., neurodegenerative conditions such as Alzheimer’s disease and Frontotemporal dementia; cardiovascular disease; chronic kidney disease; diabetic pathology conditions; and multiple oncologies including triple-negative breast cancer. After gaining his Ph.D. as the Ackroyd Brother & Brown Research Fellow in Receptor Pharmacology from the University of Leeds, he received a Howard Hughes Medical Institute Fellowship Award to train with Professor Robert Lefkowitz (2012 Nobel Laureate in Chemistry) at Duke University. He was then recruited to be the youngest Principal Investigator of the Receptor Biology Section at the Medical Research Council Human Reproductive Sciences Unit at the University of Edinburgh in the U.K. After successfully developing a line of receptor-based novel prostate cancer therapeutics at the MRC, Dr. Stuart was next recruited to the National Institutes of Health (NIH) where I worked for the next decade as the Head of the Receptor Pharmacology Unit at the NIH-National Institute on Aging at the Johns Hopkins Medical School. In addition to this, he was also a lecturer in Molecular Gerontology at the Hopkins-affiliated Bloomberg School of Public Health.
Dr. David Dworaczyk is a seasoned executive with extensive experience in the pharmaceutical and healthcare industry. Currently serving as the CEO and Head of R&D, Regulatory, and Production at Bryn Pharma, LLC since 2018, Dr. Dworaczyk played a pivotal role in establishing the corporate legal entity, developing governance processes, and fostering a collaborative team to drive corporate success. Under his leadership, the company secured approximately $125MM in non-institutional funding and formulated a robust business growth strategy.
Dr. Dworaczyk led Bryn Pharma in implementing financial and operational infrastructure for the successful development and pre-commercialization of their lead drug product. His adept leadership in team building, strategic funding, and FDA/regulatory strategy has positioned Bryn Pharma for continued success.
Miss Wu Nan was born on July 7, 1982, and got her PhD in Phytology from Northeast Forestry University in July 2013.
Dr. Wu has more than 12 years of experience in pharmaceutical scientific research and participated in the development of more than 10 domestic small molecule new drugs, three of them have been approved for market launching.
Dr. Wu joined Haisco Pharmaceutical Group Company Ltd since 2017, titled as the Vice General Manager of Haisco Group, is responsible for the general management of R&D, marketing &sales, and human resources. She built and sharpened a clinical team for innovative drugs at Haisco, and established a core technology system that runs through the entire process of drug development for the company. She optimized and expanded the R&D pipeline of innovative drugs, creating multiple leading technology platforms. She has driven dozens of preclinical candidate compounds to enter the clinical stages of Phase I, II, and III and led the team to complete multiple NDA filings for innovative new drugs.
Ahmed Elsonbaty is a seasoned pharmaceutical chemistry researcher with over six years of extensive experience in pharmaceutical analytical chemistry research. Since 2017, Elsonbaty has been actively engaged as a researcher and lecturer at the Faculty of Pharmacy, Egyptian Russian University. His notable contributions include numerous research publications in esteemed journals.
Dr. Elsonbaty earned his Doctorate in Pharmaceutical Chemistry from Suez Canal University in 2024, following the successful completion of a Master of Science in Pharmaceutical Analysis from Zagazig University's Faculty of Pharmacy in Egypt in 2022. His academic journey commenced with a Bachelor of Science in Pharmaceutical Sciences from the Faculty of Pharmacy at Ain-Shams University in Egypt in 2016.
The overarching objective guiding Dr. Elsonbaty's professional endeavors is the enhancement of research quality through the implementation of advanced pharmaceutical analysis procedures. His research specifically concentrates on the application of cutting-edge advancements in green analytical material science and computational chemistry techniques, encompassing Computational Modeling and Simulation of Molecular Spectroscopy and Reactivity, Quantum Chemistry, and Molecular Modeling, within the domain of pharmaceutical analysis.
Dr. Elsonbaty has demonstrated his scholarly prowess through the publication of several research papers, delving into diverse topics such as spectroscopy, chromatography, and electrochemical sensors. Of particular significance is the integration of computational studies, illustrating the implications and applications of these methodologies in pharmaceutical mixtures and biological samples.
Dr. Khaled Attala is a pharmaceutical chemistry researcher with over six years of experience in pharmaceutical analytical chemistry. He is currently a researcher and assistant lecturer at the Faculty of Pharmacy, Egyptian Russian University, where he has worked since 2017. He has authored and co-authored many research articles in reputable journals. He holds an MSc in Pharmaceutical Analysis from the Faculty of Pharmacy, Zagazig University, Egypt, which he obtained in 2021. He also graduated with a BSc in Pharmacy from the Faculty of Pharmacy, Ain-Shams University, Egypt 2016. His long-term goal is to enhance the quality of research by applying more advanced methodologies in pharmaceutical analysis. His research interests include integrating the latest technologies in material science and computational chemistry into pharmaceutical analysis.
Dr. Mostafa Abbas Mostafa Shalaby, a distinguished academician in the field of pharmacology, has had a prolific career spanning several decades:
Assistant Lecturer: Progressed to the role of Assistant Lecturer, showcasing early excellence in teaching and research.
Lecturer: Promoted to the position of Lecturer, contributing significantly to the academic environment.
Assistant Professor: Elevated to Assistant Professor, demonstrating expertise and commitment to pharmacology education.
Professor: Attained the esteemed position of Professor, leaving a lasting impact on students and colleagues.
Head of Pharmacology Department: Led the Pharmacology Department, demonstrating administrative and leadership skills.
Council Memberships: Served as a member of the Council of the Faculty of Veterinary Medicine, Cairo University, contributing to institutional development.
Committee Memberships: Active participant in various committees, including the Food and Drug Analysis Center and the Permanent Scientific Committee of Pharmacology and Forensic Medicine.
Veterinary Medical Syndicate Membership: Holds membership (Number 3328) in the Veterinary Medical Syndicate, Egypt.
Dr. Shalaby has left an indelible mark on the field of pharmacology through a career marked by excellence in teaching, research, and institutional service.
Dr. Eman Gamal El-Din Ezzat Helal is a Professor at Al Azhar University, Cairo, Egypt, with vast teaching experience in hematology, comparative physiology, and biochemistry. Holding a Ph.D. in Physiology, her research focused on mineralocorticoid activity in young chickens. Over her career, she has held positions from Demonstrator to Professor, contributing to the field. Prof. Helal is a member of esteemed societies including the Egyptian German Society and the Egyptian Society of Physiology, reflecting her dedication to advancing scientific knowledge.
Dr. Prachi Srivastava is an Associate Professor at Amity Institute of Biotechnology – Amity University, Uttar Pradesh, Lucknow. She completed her master’s from Lucknow University in Zoology in 1995. Her research was under a collaborative project of IITR and KGMU Lucknow in the area of Eales’ Disease Diabetic Retinopathy and Uveitis. Later, she was awarded her doctorate from Lucknow University in 2004. She developed platelets as a model system for oxidative stress studies against ‘retinal disorders’. She has made significant research contributions in bioinformatics, under which she focused on Gene identifications, High throughput analysis to protein structure predictions as well as virtual screening to identify the potentiality of herbal molecules. She is also working in the area of microarray data analysis of selected disorders as well as unique database designing and development. OcularInformatics and Neuroinformatics are her key areas of interest. She has predicted ‘different structures of ocular and neural proteins along with their characterization and docking studies of different herbal molecules.’ Beyond this, she is also working in filariasis and other allied branches of computational biology. She has presented papers in national and international forums & conferences; is recognized by journals of high repute as she has seventy-four publications and more than a hundred of her abstracts to her credit. In addition to presenting her research, she has actively organized many national and international conferences, seminars, training programs, and FDP. She has also chaired many national and international sessions of conferences as well as delivered talks and guest lectures at different national and international scientific forums and academic platforms.
Dr. Elvis Ofori Ameyaw is a Ghanaian working at the University of Cape Coast as a Professor of Pharmacology. He is the Dean of the School of Pharmacy and Pharmaceutical Sciences, College of Health and Allied Sciences (CoHAS), UCC. He obtained his Bachelor of Pharmacy Degree and PhD in Pharmacology, both from the Kwame Nkrumah University of Science and Technology, Kumasi. He further proceeded to the University of Georgia, Athens, USA, as a Fulbright Research Scholar for his Fellowship in the area of Natural Product Drug Discovery.
He is a Pharmacist and a Fellow of the Ghana College of Pharmacists and has assisted in training several pharmacists in the country. He has developed a research niche in Central Nervous System Pharmacology.